First Molecular Test to Simultaneously Identify Staphylococcus Aureus and
Methicillin-Resistant Staphylococcus Aureus from Nasal Specimens
SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA), for additional claims for the BD GeneOhmTM StaphSR assay. This will be the first assay for rapid and simultaneous identification of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) from patients colonized in the nasal passage.
The BD GeneOhm StaphSR assay is a simple test that provides results within two hours directly from nasal swabs. The assay is easy to perform and requires less technologist time than traditional microbiology algorithms, which can take two days to generate results.
Identifying patients colonized with MRSA or SA bacteria in advance of surgery helps ensure patients have an opportunity to be decolonized and receive the appropriate prophylactic antibiotics prior to surgery. This reduces the risk of a potentially deadly surgical site infection (SSI).
A recent study revealed that patients acquiring SSIs after coronary artery bypass graft (CABG) surgery had a one year mortality rate of 22 percent. This study also found that lengths of stay and costs increased by 20 days and $18,938, respectively, for this patient population.
Since the most frequent organism cultured in cardiac SSIs is
Staphylococcus sp., and colonization is considered the major factor in
wound contamination, the Society of Thoracic Surgeons issued guidelines
recommending rapid PCR screening tests for Staphylococcus
|SOURCE BD Diagnostics|
Copyright©2007 PR Newswire.
All rights reserved